Neuberger Berman Group LLC Sells 20,877 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Neuberger Berman Group LLC reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 7.8% in the first quarter, Holdings Channel reports. The fund owned 245,892 shares of the medical research company’s stock after selling 20,877 shares during the quarter. Neuberger Berman Group LLC’s holdings in Charles River Laboratories International were worth $69,870,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Charles River Laboratories International by 1.1% in the first quarter. Vanguard Group Inc. now owns 5,935,727 shares of the medical research company’s stock worth $1,685,568,000 after buying an additional 66,602 shares during the last quarter. BlackRock Inc. increased its stake in Charles River Laboratories International by 3.0% in the first quarter. BlackRock Inc. now owns 5,230,033 shares of the medical research company’s stock worth $1,485,173,000 after purchasing an additional 150,007 shares during the period. State Street Corp increased its stake in shares of Charles River Laboratories International by 3.7% during the fourth quarter. State Street Corp now owns 2,030,795 shares of the medical research company’s stock valued at $765,163,000 after buying an additional 73,315 shares during the period. Kayne Anderson Rudnick Investment Management LLC increased its stake in shares of Charles River Laboratories International by 4.8% during the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,552,655 shares of the medical research company’s stock valued at $585,009,000 after buying an additional 70,850 shares during the period. Finally, Clearbridge Investments LLC increased its stake in shares of Charles River Laboratories International by 28.2% during the first quarter. Clearbridge Investments LLC now owns 1,368,943 shares of the medical research company’s stock valued at $388,739,000 after buying an additional 301,159 shares during the period. 95.20% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Down 1.9 %

Charles River Laboratories International stock opened at $199.71 on Friday. The stock has a market capitalization of $10.16 billion, a PE ratio of 23.17, a price-to-earnings-growth ratio of 1.35 and a beta of 1.35. Charles River Laboratories International, Inc. has a 12 month low of $196.90 and a 12 month high of $460.21. The business has a 50 day simple moving average of $219.78 and a 200-day simple moving average of $239.92. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.33 and a quick ratio of 1.08.

Charles River Laboratories International (NYSE:CRLGet Rating) last posted its quarterly earnings data on Wednesday, August 3rd. The medical research company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.74 by $0.03. The business had revenue of $973.13 million during the quarter, compared to analysts’ expectations of $995.12 million. Charles River Laboratories International had a return on equity of 21.51% and a net margin of 12.02%. The business’s revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.61 earnings per share. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 10.77 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 200 shares of the business’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $226.13, for a total transaction of $45,226.00. Following the completion of the sale, the executive vice president now directly owns 20,766 shares in the company, valued at $4,695,815.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent research reports. Wells Fargo & Company dropped their price objective on Charles River Laboratories International from $325.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 16th. Morgan Stanley downgraded Charles River Laboratories International from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $350.00 to $250.00 in a report on Thursday, August 4th. Citigroup decreased their target price on Charles River Laboratories International to $280.00 in a report on Tuesday, August 9th. Deutsche Bank Aktiengesellschaft decreased their target price on Charles River Laboratories International from $290.00 to $270.00 in a report on Monday, August 8th. Finally, Stephens set a $315.00 target price on Charles River Laboratories International in a report on Monday, June 20th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus target price of $317.67.

About Charles River Laboratories International

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.